Spectrum Pharmaceuticals : Preclinical Data Demonstrates Potential Applications In Lung Cancer Therapy

April 17, 2008- Spectrum Pharmaceuticals, Inc., (Nasdaq:SPPI) announced preclinical data on lucanthone via poster presentation at the 2008 Annual Meeting of the American Association of Cancer Research (AACR), held in San Diego, California. Lucanthone is an orally administered small molecule inhibitor of DNA repair. The Company is expected to initiate shortly a Phase I dose-escalation study of lucanthone in patients with recurrent malignant gliomas receiving temozolomide. Data presented demonstrates that lucanthone improves the activity of pemetrexed (Alimta(R), Eli Lilly & Co.) in lung cancer animal models... Spectrum Pharmaceuticals' Press Release -